Most interestingly, by implementing clinically relevant genetic and pharmacological approaches, evidence is provided supporting the therapeutic potential of targeting ChREBP activity to quell HCC progression and reverse sorafenib resistance. The gene discussed is MLXIPL; the disease is hepatocellular carcinoma.